EA015978B1 - Соединения для лечения гепатита с - Google Patents

Соединения для лечения гепатита с Download PDF

Info

Publication number
EA015978B1
EA015978B1 EA201000277A EA201000277A EA015978B1 EA 015978 B1 EA015978 B1 EA 015978B1 EA 201000277 A EA201000277 A EA 201000277A EA 201000277 A EA201000277 A EA 201000277A EA 015978 B1 EA015978 B1 EA 015978B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cyclohexyl
indolo
methoxy
benzazepine
methyl
Prior art date
Application number
EA201000277A
Other languages
English (en)
Russian (ru)
Other versions
EA201000277A1 (ru
Inventor
Скотт У. Мартин
Карл П. Бергстрём
Роберт Дж. Джентлс
Кап-Сан Енг
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201000277A1 publication Critical patent/EA201000277A1/ru
Publication of EA015978B1 publication Critical patent/EA015978B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201000277A 2007-08-09 2008-08-01 Соединения для лечения гепатита с EA015978B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95481407P 2007-08-09 2007-08-09
US4994408P 2008-05-02 2008-05-02
US12/180,994 US7652004B2 (en) 2007-08-09 2008-07-28 Compounds for the treatment of hepatitis C
PCT/US2008/071881 WO2009029384A2 (en) 2007-08-09 2008-08-01 Compounds for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
EA201000277A1 EA201000277A1 (ru) 2010-06-30
EA015978B1 true EA015978B1 (ru) 2012-01-30

Family

ID=40261456

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000277A EA015978B1 (ru) 2007-08-09 2008-08-01 Соединения для лечения гепатита с

Country Status (18)

Country Link
US (1) US7652004B2 (cg-RX-API-DMAC7.html)
EP (1) EP2183252B1 (cg-RX-API-DMAC7.html)
JP (1) JP5465670B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100066492A (cg-RX-API-DMAC7.html)
CN (1) CN101821267B (cg-RX-API-DMAC7.html)
AR (1) AR067897A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008293845B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0814931A2 (cg-RX-API-DMAC7.html)
CA (1) CA2695781A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008002353A1 (cg-RX-API-DMAC7.html)
CO (1) CO6251359A2 (cg-RX-API-DMAC7.html)
EA (1) EA015978B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010001416A (cg-RX-API-DMAC7.html)
NZ (1) NZ583149A (cg-RX-API-DMAC7.html)
PE (1) PE20090618A1 (cg-RX-API-DMAC7.html)
TW (1) TW200906418A (cg-RX-API-DMAC7.html)
WO (1) WO2009029384A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201000923B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. 5-5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2209789B1 (en) * 2007-11-20 2011-11-16 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
ATE531373T1 (de) 2008-03-27 2011-11-15 Bristol Myers Squibb Co Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2396329B1 (en) * 2009-02-11 2014-10-29 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
WO2012176717A1 (ja) * 2011-06-22 2012-12-27 セントラル硝子株式会社 ピラゾール化合物の製造方法
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033032A1 (en) * 2005-09-12 2007-03-22 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007092888A2 (en) * 2006-02-08 2007-08-16 Bristol-Myers Squibb Company Hcv ns5b inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080399A1 (ja) 2004-02-24 2005-09-01 Japan Tobacco Inc. 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007119562A (ru) 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
DE602007006796D1 (de) 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033032A1 (en) * 2005-09-12 2007-03-22 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007092888A2 (en) * 2006-02-08 2007-08-16 Bristol-Myers Squibb Company Hcv ns5b inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IKEGASHIRA K. ET AL.: "Discovery of Conformationally Constrained Tetracyclic Compounds as Potent Hepatitis S Virus NS5B RNA Polymerase Inhibitors" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON., US, vol. 49, no. 24, 1 January 2006 (2006-01-01), pages 6950-6953, XP002505121 ISSN: 0022-2623 [retrieved on 2006-11-02] *

Also Published As

Publication number Publication date
US7652004B2 (en) 2010-01-26
PE20090618A1 (es) 2009-05-16
CO6251359A2 (es) 2011-02-21
TW200906418A (en) 2009-02-16
CN101821267B (zh) 2013-07-10
MX2010001416A (es) 2010-03-01
EA201000277A1 (ru) 2010-06-30
EP2183252B1 (en) 2015-01-14
KR20100066492A (ko) 2010-06-17
WO2009029384A2 (en) 2009-03-05
WO2009029384A3 (en) 2009-05-28
NZ583149A (en) 2011-07-29
CL2008002353A1 (es) 2008-10-24
AR067897A1 (es) 2009-10-28
JP5465670B2 (ja) 2014-04-09
EP2183252A2 (en) 2010-05-12
CN101821267A (zh) 2010-09-01
AU2008293845B2 (en) 2013-02-14
CA2695781A1 (en) 2009-03-05
AU2008293845A1 (en) 2009-03-05
US20090074715A1 (en) 2009-03-19
BRPI0814931A2 (pt) 2015-02-03
JP2010535787A (ja) 2010-11-25
ZA201000923B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
JP5465670B2 (ja) C型肝炎を治療するための化合物
US7473688B2 (en) Indolobenzazepine HCV NS5B inhibitors
KR102787063B1 (ko) 폴리시클릭 tlr7/8 안타고니스트 및 면역 질환의 치료에서 이들의 용도
AU2017336523B2 (en) Calpain modulators and therapeutic uses thereof
CN116670143A (zh) 囊性纤维化跨膜传导调控因子的调节剂
CN102827170A (zh) 治疗活性组合物和它们的使用方法
EA016614B1 (ru) Соединения для лечения гепатита с
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
EA024171B1 (ru) Ингибиторы вируса гепатита с
CN103827108B (zh) 丙型肝炎病毒抑制剂
JP2017538766A (ja) 縮合環ヘテロアリール化合物及びtrk抑制剤としての用途
HK1211293A1 (en) Bruton's tyrosine kinase inhibitors
EP3924340B1 (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
US8133884B2 (en) Compounds for the treatment of hepatitis C
CA3146715A1 (en) Substituted amino triazoles useful as chitinase inhibitors
US8143243B2 (en) Compounds for the treatment of hepatitis C
WO2023072301A1 (zh) 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途
JP2012517468A (ja) C型肝炎治療のための化合物
RU2783748C2 (ru) Полициклические антагонисты tlr7/8 и их применение в лечении иммунных расстройств

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU